Dr. Cecelia Constance Damask, DO

Dr. Damask practices at South Florida ENT Associates, Inc. in Orlando, Florida.

Dr. Damask's NPI, 1790756955, was assigned on January 27, 2006. Dr. Damask graduated from Chicago College of Osteopathic Medicine at Midwestern University in 1999. Dr. Damask holds Florida license OS9704.

Dr. Damask's primary practice is South Florida ENT Associates, Inc., at 11317 Lake Underhill Rd Suite 100 Suite 100, Orlando, FL 32825-4452. The practice phone is (407) 955-4948.

Dr. Damask's primary practice is South Florida ENT Associates, Inc. in Orlando, Florida. Dr. Damask is also affiliated with AdventHealth Orlando. The medical group on file is South Florida ENT Associates. Dmand AI also links Dr. Damask to 1 more physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Damask practices, 3 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Damask's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Damask is board certified in otolaryngology/facial plastic surgery by the AOA Board of Ophthalmology and Otolaryngology. Dr. Damask is licensed in Florida.

Dmand AI lists acute sinusitis, chronic nasal allergies, ear eustachian tube disorders, hearing loss and impairment, swimmer's ear and tinnitus among the conditions Dr. Damask treats.

CMS data shows 327 Medicare services from Dr. Damask across 8 procedure codes in 2024, for 173 Medicare patients. Medicare paid $22,125 for them. Every service was in an office.

CMS counts 173 Medicare patients who saw Dr. Damask in 2024. The largest group is 65 to 74, with 88 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.12, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Damask's median patient age at 47, with 57% women.

In 2024, Dr. Damask wrote 391 Medicare Part D claims for 126 patients. 53% of them were for generic drugs. CMS names the drug for 277 of them, across 10 drugs with 11 or more claims each, at $36,426 in total drug cost. In 2023, CMS named 393 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 70 out of 100 for Dr. Damask for performance year 2024, reported as part of a group. Dr. Damask accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Damask, published from 2020 to 2025. The most frequent topics are Rhinitis, Allergic, Allergens and Asthma. Dr. Damask has published most often in Otolaryngol Head Neck Surg. Dr. Damask's most frequent co-authors are Fuad M. Baroody, Christine Blanche Franzese, MD and Robert John Stachler, MD.

Dmand AI links Dr. Damask to 4 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Asthma, Nasal Polyps and Pathological Conditions, Signs and Symptoms. AstraZeneca sponsors the most, 2.

CMS Open Payments shows 1,246 general payments to Dr. Damask from 35 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 67% of the total. Sanofi and Genzyme US Companies paid the most, $298,960. It also lists 20 research payments totaling $23,800 from 2018 to 2023.

Dmand AI lists 1 award for Dr. Damask. Dr. Damask serves on AAOHNS Allergy Asthma & Immunology Committee and AAOHNSF Annual Meeting Program Committee.

Dr. Damask graduated from Chicago College of Osteopathic Medicine at Midwestern University in 1999. Dr. Damask is a member of NHS and AOA.

Dr. Damask is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.